MAP2K1 and metastatic neoplasm: Despite the absence of additional MAPK mutations, melanomas with Class II and III MAP2K1 mutations progressed to metastasis in one-eighth and one-third of cases, respectively, with the presence of TERT-p mutations being an independent predictor for metastatic disease.